WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Anticoagulant_Master_CMAP_v6, Time to the first occurrence of Non-CNS systemic embolism (SEE) has_components CRF: Non-CNS systemic embolism (SEE), Safety endpoint has_options CRF: Adverse event (AE)s, Time to the first occurrence of stroke has_component CRF: Stroke, Study visit has_component Date of visit, Safety endpoint has_options Hepatotoxicity, Primary efficacy endpoints has_options Time to the first occurrence of Non-CNS systemic embolism (SEE), FDA Efficacy Endpoints for Anticoagulant Therapy refers_to Safety endpoint, Study visit has_component Type of visit, Repeated concepts/instances (e.g. Stroke, Death) are denoted by dotted outline, Secondary efficacy endpoint has_compnents Individual secondary endpoints, Safety endpoint has_options Incidence of bleeding events, Incidence of bleeding events has_component Bleeding events, CRF: Non-CNS systemic embolism (SEE) is_documented_at Study visit, Concepts which may be removed (for simplicity) are denoted by Gray shading, CRF: Non-CNS systemic embolism (SEE) occurs_during Timepoints, Concepts (e.g. Study visit) are denoted by solid round-edged rectangle, Liver function test (LFT) is_documented_at Timepoints, FDA Efficacy Endpoints for Anticoagulant Therapy refers_to Secondary efficacy endpoint, Primary efficacy endpoints are denoted by bold font, Hepatotoxicity has_component Liver function test (LFT)